Abstract
Docetaxel (Taxotere) is a taxoid derived from the European yew tree, taxus baccata. In 4 phase-II studies docetaxel has important single agent activity with an overall prostate-specific antigen response rate of 42% in hormone refractory prostate cancer. Other phase-II studies suggest that the addition of estramustine to docetaxel results in a higher response rate but also in an increased toxicity. At present Docetaxel with and without estramustine is being evaluated in phase-III studies that will provide definitive information about its role in hormone refractory prostate cancer.
Copyright 2003 S. Karger GmbH, Freiburg
MeSH terms
-
Antineoplastic Agents, Phytogenic / administration & dosage*
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / toxicity
-
Biomarkers, Tumor / blood
-
Clinical Trials as Topic
-
Docetaxel
-
Estramustine / administration & dosage
-
Estramustine / toxicity
-
Humans
-
Male
-
Neoplasm Staging
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / drug therapy*
-
Prostatic Neoplasms / pathology
-
Taxoids / administration & dosage*
-
Taxoids / toxicity
Substances
-
Antineoplastic Agents, Phytogenic
-
Biomarkers, Tumor
-
Taxoids
-
Docetaxel
-
Estramustine
-
Prostate-Specific Antigen